Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

NCT06441110 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Urinary Bladder Neoplasms
BCG Vaccine
Immunotherapy, Active
Multicenter Study
Treatment Outcome
Neoplasm Recurrence, Local

Interventions

DRUG: Tislelizumab in Combination with Bacillus Calmette-Guérin

Sponsor

Fujian Medical University Union Hospital